Prolactin-producing pituitary tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Prolactin-producing pituitary tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparison of Surgical Treatment versus Cabergoline in Patients with Newly Diagnosed Microprolactinomas https://clinicaltrials.eu/trial/study-comparing-surgery-and-cabergoline-for-treating-microprolactinomas-in-newly-diagnosed-patients/ Wed, 29 Apr 2026 14:59:12 +0000 https://clinicaltrials.eu/trial/study-comparing-surgery-and-cabergoline-for-treating-microprolactinomas-in-newly-diagnosed-patients/ This study focuses on patients with microprolactinomas, which are small tumors in the pituitary gland that produce excess amounts of a hormone called prolactin. The research compares two different treatment approaches: surgical removal of the tumor through a procedure called endoscopic endonasal surgery and medical treatment with a drug called cabergoline (Dostinex).

The research aims to determine if surgical treatment works as well as the standard medical treatment in controlling hormone levels. During the study, some patients will receive the medication cabergoline as tablets taken by mouth, while others will undergo surgery to remove the tumor. The medication will be given at a maximum daily dose of 0.5 milligrams, with treatment lasting up to 12 months.

Throughout the study, patients will have their prolactin hormone levels checked through blood tests. They will also undergo magnetic resonance imaging (MRI) scans to monitor the size of the tumor. These evaluations will help determine how well each treatment method works in controlling the condition and reducing the tumor size.

]]>